Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for review the company's supplemental new drug application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel to treat primary generalized tonic-clonic seizures, a severe form of seizures, in patients 12 years and older.